Assessment of the clinical benefit of administering the lapatinib and trastuzumab combination with chemotherapy for operable HER2‐positive breast cancer has proved positive 7, but replacement of lapatinib with trastuzumab as first‐line targeted therapy in breast cancer has demonstrated conflicting results. The gene discussed is ERBB2; the disease is breast carcinoma.